Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Monopar Therapeutics (MNPR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $100.00 price target on the stock.
Monopar Therapeutics GAAP EPS of -$0.61 misses by $0.16 [Seeking Alpha]
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer